Zenas BioPharma, Inc. (ZBIO)
Automate Your Wheel Strategy on ZBIO
With Tiblio's Option Bot, you can configure your own wheel strategy including ZBIO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ZBIO
- Rev/Share 0.3588
- Book/Share 6.8017
- PB 1.3996
- Debt/Equity 0.0043
- CurrentRatio 6.4684
- ROIC -0.6097
- MktCap 398261422.0
- FreeCF/Share -3.2954
- PFCF -2.8912
- PE -2.4419
- Debt/Assets 0.0037
- DivYield 0
- ROE -0.9767
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ZBIO | Wedbush | -- | Outperform | -- | $35 | March 20, 2025 |
| Initiation | ZBIO | Wolfe Research | -- | Outperform | -- | $19 | Feb. 4, 2025 |
| Initiation | ZBIO | H.C. Wainwright | -- | Buy | -- | $30 | Dec. 16, 2024 |
| Initiation | ZBIO | Morgan Stanley | -- | Overweight | -- | $40 | Oct. 8, 2024 |
| Initiation | ZBIO | Jefferies | -- | Buy | -- | $35 | Oct. 8, 2024 |
| Initiation | ZBIO | Guggenheim | -- | Buy | -- | $45 | Oct. 8, 2024 |
| Initiation | ZBIO | Citigroup | -- | Buy | -- | $27 | Oct. 8, 2024 |
News
Shareholders of Zenas BioPharma, Inc. Should Contact The Gross Law Firm Before June 16, 2025 to Discuss Your Rights - ZBIO
Published: April 21, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , April 21, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO). Shareholders who purchased shares of ZBIO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
Levi & Korsinsky Reminds Zenas BioPharma, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 16, 2025 - ZBIO
Published: April 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 20, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=144126&wire=1 or contact Joseph E. Levi, Esq.
Read More
ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: April 20, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , April 20, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Zenas BioPharma, Inc. ("Zenas BioPharma" or "the Company") (NASDAQ: ZBIO) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Zenas BioPharma securities pursuant to the registration statement and prospectus issued in connection with the Company's September 13, 2024 initial public offering ("IPO").
Read More
Class Action Filed Against Zenas BioPharma, Inc. (ZBIO) - June 16, 2025 Deadline to Join - Contact Levi & Korsinsky
Published: April 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 20, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=144113&wire=1 or contact Joseph E. Levi, Esq.
Read More
June 16, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - ZBIO
Published: April 18, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 18, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=143881&wire=1 or contact Joseph E. Levi, Esq.
Read More
ZBIO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: April 17, 2025 by: Business Wire
Sentiment: Neutral
SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements re: Zenas BioPharma business and prospects, resulting in its stock trading at inflated prices.
Read More
ZBIO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Published: April 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 16, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Zenas BioPharma, Inc. ("Zenas BioPharma" or "the Company") (NASDAQ:ZBIO) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Zenas BioPharma securities pursuant to the registration statement and prospectus issued in connection with the Company's September 13, 2024 initial public offering ("IPO").
Read More
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Zenas BioPharma, Inc. – ZBIO
Published: April 16, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with Zenas BioPharma's September 2024 initial public offering (the “IPO”). The lawsuit seeks to recover damages for Zenas BioPharma investors under.
Read More
Zenas BioPharma, Inc. Investor News: If You Have Suffered Losses in Zenas BioPharma, Inc. (NASDAQ: ZBIO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Published: April 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO) resulting from allegations that Zenas BioPharma may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Zenas BioPharma securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Zenas BioPharma, Inc. Investors to Inquire About Securities Class Action Investigation - ZBIO
Published: April 08, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / April 8, 2025 / WHY: New York, N.Y., April 8, 2025.
Read More
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Quantum Computing Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – QUBT
Published: April 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 04, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Quantum Computing Inc. (NASDAQ: QUBT) between March 30, 2020 and January 15, 2025, both dates inclusive (the “Class Period”), of the important April 28, 2025 lead plaintiff deadline.
Read More
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Game of Silks NFT Investors to Secure Counsel Before Important Deadline in Securities Class Action
Published: April 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 04, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Game of Silks non-fungible tokens (“NFTs”), including Silks Avatar NFTs, Silks Horse NFTs, and Silks Land NFTs, and who were damaged thereby, of the important April 25, 2025 lead plaintiff deadline.
Read More
Zenas BioPharma, Inc. Announcement: If You Have Suffered Losses in Zenas BioPharma, Inc. (NASDAQ: ZBIO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Published: April 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO) resulting from allegations that Zenas BioPharma may have issued materially misleading business information to the investing public.
Read More
ZBIO Investor News: Rosen Law Firm Encourages Zenas BioPharma, Inc. Investors to Inquire About Securities Class Action Investigation - ZBIO
Published: March 31, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 31, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO) resulting from allegations that Zenas BioPharma may have issued materially misleading business information to the investing public. So What: If you purchased Zenas BioPharma securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
ZBIO Investor News: Rosen Law Firm Encourages Zenas BioPharma, Inc. Investors to Inquire About Securities Class Action Investigation - ZBIO
Published: March 26, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 26, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO) resulting from allegations that Zenas BioPharma may have issued materially misleading business information to the investing public. So What: If you purchased Zenas BioPharma securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Zenas BioPharma, Inc. Announcement: If You Have Suffered Losses in Zenas BioPharma, Inc. (NASDAQ: ZBIO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO) resulting from allegations that Zenas BioPharma may have issued materially misleading business information to the investing public.
Read More
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Zenas BioPharma, Inc. Investors to Inquire About Securities Class Action Investigation - ZBIO
Published: March 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 24, 2025 / WHY: New York, N.Y., March 24, 2025.
Read More
ZBIO Investor News: Rosen Law Firm Encourages Zenas BioPharma, Inc. Investors to Inquire About Securities Class Action Investigation - ZBIO
Published: March 21, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 21, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO) resulting from allegations that Zenas BioPharma may have issued materially misleading business information to the investing public. So What: If you purchased Zenas BioPharma securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
About Zenas BioPharma, Inc. (ZBIO)
- IPO Date 2024-09-13
- Website https://zenasbio.com
- Industry Biotechnology
- CEO Mr. Leon Oliver Moulder Jr., M.B.A.
- Employees 130